Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

Erdafitinib, an inhibitor of fibroblast growth factor receptor, was tested in previously treated patients with advanced urothelial cancer with FGFR alterations. The objective response rate was 40%, with treatment-related adverse events of grade 3 or higher reported in nearly half the patients.

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 381; no. 4; pp. 338 - 348
Main Authors Loriot, Yohann, Necchi, Andrea, Park, Se Hoon, Garcia-Donas, Jesus, Huddart, Robert, Burgess, Earle, Fleming, Mark, Rezazadeh, Arash, Mellado, Begoña, Varlamov, Sergey, Joshi, Monika, Duran, Ignacio, Tagawa, Scott T, Zakharia, Yousef, Zhong, Bob, Stuyckens, Kim, Santiago-Walker, Ademi, De Porre, Peter, O’Hagan, Anne, Avadhani, Anjali, Siefker-Radtke, Arlene O
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 25.07.2019
Subjects
Adult
Aged
Aged, 80 and over
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Antitumor activity
Bladder cancer
Cancer
Chemotherapy
Creatinine
Drug dosages
Editorials
Enzyme inhibitors
Fibroblast growth factor receptor 1
Fibroblast growth factor receptors
Gene expression
Humans
Immune clearance
Immunotherapy
Kaplan-Meier Estimate
Kinases
Life Sciences
Metastases
Metastasis
Middle Aged
Mutation
Neoplasm Metastasis - drug therapy
Pharmaceutical sciences
Progression-Free Survival
Protein Kinase Inhibitors - administration & dosage
Protein-tyrosine kinase
Protein-Tyrosine Kinases - antagonists & inhibitors
Pyrazoles - administration & dosage
Pyrazoles - adverse effects
Quinoxalines - administration & dosage
Quinoxalines - adverse effects
R&D
Receptors, Fibroblast Growth Factor - antagonists & inhibitors
Receptors, Fibroblast Growth Factor - genetics
Research & development
Response rates
Survival
Treatment Outcome
Urologic Neoplasms - drug therapy
Urologic Neoplasms - genetics
Urologic Neoplasms - pathology
Urothelial carcinoma
Urothelium
Online AccessGet full text

Cover

More Information
Summary:Erdafitinib, an inhibitor of fibroblast growth factor receptor, was tested in previously treated patients with advanced urothelial cancer with FGFR alterations. The objective response rate was 40%, with treatment-related adverse events of grade 3 or higher reported in nearly half the patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa1817323